The 2026 AACI Leadership Development Workshop will be held in conjunction with the 2026 AACI/CCAF Annual Meeting.
This event convenes emerging leaders for didactic and experiential leadership development sessions. An offshoot of Dr. Caryn Lerman’s AACI presidential initiative, the workshop aims to enhance the oncology leadership pipeline with top talent.
Support Opportunities
AACI Update | October 2026
Headlines
Tuveson Named Director of Duke Cancer Institute
David Tuveson, MD, PhD, will step into the role of executive director of the Duke Cancer Institute, a National Cancer Institute-Designated Comprehensive Cancer Center, on October 31. He is currently director of the Cold Spring Harbor Laboratory Cancer Center and chief scientist for the Lustgarten Foundation for Pancreatic Cancer Research. Since developing the first mouse model of pancreatic cancer in 2002, discoveries by his lab team have revealed the molecular drivers of this disease and have led to promising new treatment options.
Messersmith Named Director of CU Anschutz Cancer Center
Following a nationwide search, Wells Messersmith, MD, has been named director of the University of Colorado Anschutz Cancer Center, effective October 1. As the fourth director in the 41-year history of Colorado’s only NCI-Designated Comprehensive Cancer Center, Dr. Messersmith will oversee research, patient care, workforce development, and community outreach and education.
Mitchell Selected to Lead UF Health Cancer Institute
Duane A. Mitchell, MD, PhD, began in his new role as director of the UF Health Cancer Institute on September 21. Dr. Mitchell previously served as director of the UF Clinical and Translational Science Institute and is co-director of the Preston A. Wells Jr. Center for Brain Tumor Therapy. As director, he will lead the cancer institute in its mission to expand its research portfolio, promote community engagement, and impact patient success as part of its long-term goal of National Cancer Institute Comprehensive Cancer Center designation.
Kalluri Appointed to Leadership Roles at UT Medical Branch Cancer Center
Raghu Kalluri, MD, PhD, took the helm at the University of Texas Medical Branch Cancer Center as executive director, senior vice president, and chief scientific officer on September 1. As the cancer center's leader, Dr. Kalluri will support the center's commitments to advancing scientific discovery and expanding access to innovative cancer care. An internationally recognized cancer researcher, Dr. Kalluri was previously chair of Cancer Biology and director of the Metastasis Research Center at The University of Texas MD Anderson Cancer Center.
Executive Coach to Deliver Annual Meeting Keynote
Peter A. James, PhD, will deliver the opening keynote of the 2026 AACI/CCAF Annual Meeting at 2:00 pm central time on Sunday, October 25. Dr. James, president and CEO of HCG Strategic Partners, will share how cancer center leaders can implement lasting, meaningful change at their institutions.
AACI CARDS Webinar: Transforming Cancer Registry Data to Community Impact
AACI will host a Catchment Area Research Data Science (CARDS) webinar titled "Transforming Cancer Registry Data to Community Impact" at 2:00 pm eastern time on Tuesday, October 13. The webinar will highlight innovative collaborations between cancer centers and registries to extend the use of population-based cancer data.
IgniteData and AACI to Present Webinar: One Platform, Every Study
IgniteData and AACI will present a webinar titled “One Platform, Every Study” at 2:00 pm eastern time on Wednesday, October 14. This AACI Tech Gold webinar will feature the partners behind IgniteData’s Archer platform, which connects electronic health record data to any electronic data capture (EDC) software.
AACI Call for Nominations: CTI and PCLI Steering Committees
AACI is accepting nominations for the Cellular Therapy Initiative (CTI) and Physician Clinical Leadership Initiative (PCLI) steering committees till 5:00 pm Pacific time on Friday, October 30. This election cycle, AACI will select two new CTI Steering Committee members and three new PCLI Steering Committee members, with selected members beginning a three-year term in January 2027.
Policy Roundup: NIH Grant Review Changes Dropped, NCI Budget Announced
As part of its commitment to amplifying the impact of cancer centers in Washington, AACI monitors cancer-related public policy and participates in advocacy activities on behalf of the cancer research community. Last month, AACI weighed in on a proposed executive order that would have impacted federal grant review, the National Cancer Institute announced its Fiscal Year 2028 Professional Judgment Budget, and AACI supported the Rally for Medical Research and Congressional Women's Softball Game. Looking ahead, AACI will host the Fall 2026 Government Relations Forum during the 2026 AACI/CCAF Annual Meeting, and planning is underway for the 2027 AACI/AACR Hill Day.
Save the Dates for 2027 AACI Meetings
AACI has scheduled its 2027 meetings and conferences. Please mark your calendars for the 2027 AACI/AACR Hill Day, 2027 Catchment Area Data Excellence (CADEx) Conference, 19th Annual AACI Clinical Research Innovation (CRI) Meeting, 2027 AACI/CCAF Annual Meeting, and 2027 AACI Leadership Development Workshop.
News from the Centers
Eberlein Installed as President of American College of Surgeons
Siteman Cancer Center
Timothy J. Eberlein, MD, FACS, director of Siteman Cancer Center at Barnes-Jewish Hospital and WashU Medicine, has been installed as the 107th president of the American College of Surgeons, the world’s largest organization of surgeons.
Rosenzweig Elected Vice Chair of ASTRO Education Council
Mount Sinai Tisch Cancer Center
Kenneth Rosenzweig, MD, was elected the incoming vice chair of the Education Council of the American Society for Radiation Oncology (ASTRO), the world’s premier radiation oncology society. He currently chairs ASTRO’s Annual Meeting Scientific Committee and has led the task force that developed the society’s small cell lung cancer guideline.
Ferraro, Choi Recognized for Leukemia Research
Siteman Cancer Center
WashU Medicine researchers Francesca Ferraro, MD, PhD, and Jaebok Choi, PhD, at Siteman Cancer Center each have received an Award for Research Careers in Hematology from the American Society of Hematology.
IU Establishes Neuro-Oncology Research Center Through $10M Gift
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
The Indiana University Melvin and Bren Simon Comprehensive Cancer Center will accelerate brain cancer and neuro-oncology research through the new Jeff Schwarz Center for Neuro-Oncology Research, established with a $10 million gift from Schwarz's family. The newly established Schwarz Center will advance research to understand brain cancer, brain metastases, and other neuro-oncology conditions while fostering collaborations among basic scientists, translational researchers, and clinicians to accelerate new therapies for patients.
Fred Hutch Awarded $3.7M Grant to Study Aging After Childhood Cancer
Fred Hutch Cancer Center
Kavita Dhodapkar, MD, MBBS, of Fred Hutch Cancer Center and Seattle Children’s, and Smita Bhatia, MD, MPH, of the University of Alabama at Birmingham, received a five-year, $3.7 million R01 from the National Institute on Aging to investigate how immune aging may influence long-term health outcomes in survivors of pediatric cancer. Survivors of pediatric cancers are at higher risk of getting age-related conditions, like heart disease and secondary cancers, at younger-than-average ages.NCI Grants $3.46M to Study AML Biomarkers, Treatment Resistance in Older Adults
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
The NCI awarded a five-year, $3.46 million grant to researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and the University of California San Francisco to study why some patients with acute myeloid leukemia (AML), a type of blood cancer that affects more than 20,000 Americans annually, respond to treatment while others don't. Most patients over age 60 with AML die of the disease within a short time. The findings could help doctors know which patients will benefit from certain therapy before treatment begins.Wilmot Receives $3M for Pancreatic Cancer Research
Wilmot Cancer Institute, UR Medicine
The National Cancer Institute awarded a $3 million U01 grant through the Metastasis Research Network (MetNet) to co-investigators Darren Carpizo, MD, PhD; Paula Vertino, PhD; and Brian Altman, PhD. The research team has begun a new multi-investigator project, unifying separate discoveries from the Wilmot Cancer Institute on how tumors hide from the immune system and spread, aided by a cell’s 24-hour “sleep-wake” cycle.
$2.8M Federal Grant Awarded for Acral Melanoma Research
Sidney Kimmel Comprehensive Cancer Center at Jefferson
Sidney Kimmel Cancer Center at Jefferson and Moffitt Cancer Center researchers have received $2.8 million in federal funding to investigate new treatment strategies for acral melanoma, a rare, hard-to-treat form of melanoma that develops on the palms of the hands, soles of the feet, and beneath the nails. The collaborative project, "Identification and Evaluation of Immune and Targeted Therapies for Acral Melanoma," is supported through the Focused Program Award for Rare Melanomas. The research is led by Keiran Smalley, PhD, of Moffitt, with Andrew E. Aplin, PhD, of Sidney Kimmel Comprehensive Cancer Center at Jefferson, serving as collaborating principal investigator.
Researcher Awarded $2.9M to Study Prostate Cancer Screening Gap Among Black Men
Stephenson Cancer Center, University of Oklahoma
A five-year, $2.9 million grant from the National Institutes of Health will allow researchers led by Adam Alexander, PhD, to conduct a clinical trial testing Connect2Care, which educates users about prostate cancer and guides them through using an at-home PSA blood test, which is then analyzed in a certified laboratory.
UNM Comprehensive Cancer Center Earns NCI Redesignation
University of New Mexico Comprehensive Cancer Center
The UNM Comprehensive Cancer Center has earned redesignation as an NCI Comprehensive Cancer Center. The status, awarded every five years by the National Cancer Institute (NCI), places UNM Comprehensive Cancer Center among the top 3.8 percent of cancer centers nationwide. Yolanda Sanchez, PhD, is director and CEO of the cancer center and a member of AACI's Board of Directors.
TICaRT Collaboration Leads to NCI Grant Targeting Virus
UF Health Cancer Institute
The National Cancer Institute awarded a multiple-principal investigator R01 grant to UF Health Cancer Institute’s Team-based Interdisciplinary Cancer Research Training, or TICaRT, program. The research team aims to develop a new way to treat cancers caused by Kaposi sarcoma-associated herpesvirus, or KSHV.
Takebe Named Leader of Early-Phase Clinical Trials and Developmental Therapeutics Program
Wilmot Cancer Institute, UR Medicine
Naoko Takebe, MD, PhD, joined University of Rochester Medicine on September 1 as a professor of medicine and associate director for clinical research at Wilmot Cancer Institute, and director of the Early Phase Therapy Clinic at Wilmot. She will lead a new Wilmot research initiative for developmental therapeutics.
Chakraborty Appointed Associate Director of Shared Resources
Mount Sinai Tisch Cancer Center
Goutam Chakraborty, PhD, an assistant professor in the departments of Urology and Oncological Sciences, has been appointed as associate director of shared resources at Mount Sinai Tisch Cancer Center. In this role, Dr. Chakraborty will support and strengthen the scientific infrastructure that enables cutting-edge cancer research.
Mrksich Named Associate Director for Translational Research
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Milan Mrksich, PhD, has been named associate director for translational research at the Lurie Cancer Center. In this role, he will oversee the development and coordination of translational science across both the Evanston and Chicago campuses and drive initiatives to develop new therapies from the laboratory to the clinic.
Makowski Appointed Professor of Molecular Medicine and Therapeutics at Ohio State
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Liza Makowski, PhD, whose research explores connections among metabolism, the immune system, and cancer, has been appointed professor of Molecular Medicine and Therapeutics at The Ohio State University College of Medicine. Dr. Makowski previously held faculty appointments at the University of Tennessee Health Science Center.
Obesity May Remove a Natural Defense Against Breast Cancer
Huntsman Cancer Institute at the University of Utah
Huntsman Cancer Institute research team has found that obesity prevents a biological process that kills cancerous cells. The study found lean adipocytes produce more 9S-HODE, which plays an important role in purging old and damaged cells, than obese adipocytes. Keren Hilgendorf, PhD, was senior author of the study, published in Science.
A New Frontier at the Intersection of Aging and Cancer
Fox Chase Cancer Center, Temple Health
As populations age, the urgency of understanding how aging influences cancer continues to grow. At Fox Chase, the research of Mitchell “Mitch” Fane, PhD, centers on understanding how immune cells change over time and whether those changes can be reversed. His lab collects immune cells from patients of different ages and pairs them with cancer cells to observe how younger and older immune systems respond to tumors.
CARE Study Reports Complete Regression of Liver Cancer in Child Treated With Novel Immunotherapy
Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine
A new report in the New England Journal of Medicine by researchers at Baylor College of Medicine, Texas Children’s Hospital, and Seattle Children’s describes a complete regression of hepatoblastoma, the most common pediatric liver cancer, in a 3-year-old treated with a novel immunotherapy. The patient is enrolled in the CARE study, a first-in-human, Phase I trial evaluating glypican-3-specific chimeric antigen receptor T cells armed with interleukin-15 and -21.
Emotional Health Supports Physical Health in Survivors of Childhood Cancer
Comprehensive Cancer Center St. Jude Children's Research Hospital
Survivors of childhood cancer face similar emotional challenges as their peers, but also live with the knowledge they are at higher risk of developing chronic conditions earlier in life. For many, that awareness can become a source of stress, leading Rachel Tillery Webster, PhD, to study the long-term impacts of stress on biological health.
FDA Approves Targeted Therapy for Metastatic Pancreatic Cancer
UCLA Jonsson Comprehensive Cancer Center
The U.S. Food and Drug Administration has approved daraxonrasib for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. The approval follows results from an international phase 3 study co-led by UCLA that showed the targeted therapy significantly extended overall survival and reduced the risk of death by 60% compared with standard chemotherapy.Improving Outcomes After Bladder Removal
The University of Kansas Cancer Center
Researchers at KU Cancer Center found no statistically significant difference in post-operative infections and other complications between patients who received an immunonutrition drink for five days preceding radical cystectomy and those who did not, but the survival rate was higher for group that received it. The study, published in JAMA Network Open, was led by Jill Hamilton-Reeves, PhD.
Landmark Discovery Still Recognized as Foundation of Modern Cancer Immunotherapy 50 Years Later
Tampa General Hospital Cancer Institute
A Science Landmark Perspective authored by Rafi Ahmed, PhD, and Steven Rosenberg, MD, PhD, marked the 50th anniversary of Robert C. Gallo, MD and his colleagues’ discovery of a T-cell growth factor, later known as interleukin-2. The Perspective examines the discovery’s impact on cancer immunotherapy and how the ability to grow human T cells helped enable subsequent advances in cellular immunotherapy.
Loss of Y Chromosome in Men Could be Early Warning Sign of Cancer
The University of Arizona Cancer Center
A University of Arizona Cancer Center study initiated by Dan Theodorescu, MD, PhD, recently published in JCI Insights, revealed the loss of the Y chromosome in men’s body tissue could pave the way for cancer to develop in that tissue. The loss of the chromosome, which is common in men as they age, creates a pre-neoplastic field effect, a hidden zone of genetic vulnerability in normal tissue, according to the study.
New Assay Better Predicts Treatment for Two Cancers
Fred Hutch Cancer Center
Fred Hutch researchers developed HRDefine, a clinical test designed to help guide treatment decisions for people with tubo-ovarian and triple-negative breast cancers.
New Drug With UCSF Roots Has Revolutionized Pancreatic Cancer Care
UCSF Helen Diller Family Comprehensive Cancer Center
From finding ways to drug "undruggable" cancers to mRNA vaccines to CAR T: recent FDA-approved therapies are just the beginning of a new age. UC San Francisco researchers took on one of science’s lost causes and their work has finally ushered in hope for pancreatic cancer — one of medicine’s most devastating diseases.
New MRI Approach Detects Tiny Lung Tumors and Metastases in Preclinical Study
Winship Cancer Institute of Emory University
A new MRI approach using a specialized contrast agent that attaches to collagen made tiny lung tumors and early signs of cancer spread more visible in animal models, including several small lesions that CT scans failed to detect, according to research published in Science Advances. The findings suggest that the technology could one day help physicians detect lung cancer and metastases earlier while also providing clues about how invasive a tumor may be.
New Oral Nanomedicine Boosts Effectiveness of Cancer Immunotherapies
University of Michigan Rogel Cancer Center
Rogel Cancer Center researchers developed an oral drug that can increase the ability of T cells to attack tumors. To do so, they used 3,4-dihydroxybenzoic acid, or DHB, that is produced by gut bacteria. The study was published in Nature Nanotechnology.
New Recommendations Address Cancer in Latinos and All Populations
Mays Cancer Center at UT Health San Antonio MD Anderson
A new book, “Advancing Cancer Research for Latinos and All Populations: 2026 Conference Proceedings,” shares innovative research and recommendations to reduce cancer among Latinos and all people. The book highlights the results of the same-named conference from UT Health San Antonio that brought researchers, advocates, and survivors to San Antonio in February 2026.
Study Reveals New Clues to Treatment Resistance in Deadly Melanoma
Sidney Kimmel Comprehensive Cancer Center at Jefferson
A Thomas Jefferson University study published in the research journal Cancers, found a combination of defactinib and avutometinib did not produce tumor shrinkage in 12 people with metastatic uveal melanoma (MUM). A novel technology called “synthetic lethality analysis” had indicated the drug combination should work to block two different pathways and suppress the growth of MUM cancer cells. After two treatment cycles, six patients had stable diseasew, while six patients’ disease worsened.Study: Supplement With Chemo Boosts Pancreatic Cancer Survival
Cedars-Sinai Cancer
When added to standard chemotherapy, a clinical version of the dietary supplement L-glutamine improved survival in an early-phase trial of patients with advanced pancreatic cancer. The study was published in Nature Cancer. While the amino acid has been studied as a potential way to ease side effects in other cancers, this was the first trial to evaluate it as an anti-cancer therapy in human patients, according to authors.
Targeting Calcium Could Improve Brain Cancer Outcomes
University of Virginia Cancer Center
Roger Abounader, MD, PhD, led a UVA Comprehensive Cancer Center study suggesting an existing calcium-blocking drug, the FDA-approved mibefradil, combined with existing treatments, could make tumor cells easier to kill and improve patient outcomes for patients with glioblastoma.
Wistar Scientists Identify Connection Between Nervous System and Aggressive Prostate Cancer
The Wistar Institute
A new study from The Wistar Institute has found a link between the nervous system and the rapid development of neuroendocrine prostate cancer, an aggressive form of the disease. Published in Oncogene, the study found high levels of neuromedin U, a neurotransmitter that supports tumor progression by blocking the immune response. These findings could present a target for therapy for what is now a virtually untreatable disease.
Study Highlights Promising New Option for Skin Cancer Reconstruction
Fox Chase Cancer Center, Temple Health
Researchers at Fox Chase Cancer Center have identified a promising new approach to rebuilding tissue after skin cancer surgery that could help some patients avoid more extensive reconstructive procedures. Published in Plastic and Reconstructive Surgery – Global Open, the study is the largest published case series to date evaluating the DermiSphere® Hydrogel Dermal Regeneration Template from Fesarius Therapeutics, a hydrogel-based template that serves as a scaffold that encourages the body's own cells to regenerate healthy tissue.
FDA Approves PET Imaging Agent for Brain Cancer Based on UCSF Data
UCSF Helen Diller Family Comprehensive Cancer Center
UC San Francisco multi-year study data was instrumental in the U.S. Food and Drug Administration (FDA) approval of floretyrosine F 18, a PET imaging agent that helps physicians evaluate gliomas. The agent addresses a persistent challenge in caring for people with gliomas: determining whether changes seen on conventional imaging represent tumor growth or changes caused by treatment.
Paper Offers First Clinical Guidance in U.S. on E-Cigarettes for Smoking Cessation
The University of Kansas Cancer Center
A new paper led by Eleanor Leavens, PhD, of The University of Kansas Cancer Center’s Cancer Prevention and Control research program, provides the first clinical recommendations in the United States on how e‑cigarettes can be used to help adults quit smoking. Developed by the Harm Reduction Workgroup of the Society for Research on Nicotine and Tobacco and published in JAMA, the guidance is expected to influence national treatment standards and reshape how clinicians support people who smoke.
Walking Reduces Fatigue in Colorectal Cancer Survivors
Cedars-Sinai Cancer
Consistent physical activity—especially walking—can reduce fatigue and improve quality of life for colorectal cancer survivors, according to a study led by Cedars-Sinai Health Sciences University investigators. Historically, nearly 40 percent of survivors have reported persistent fatigue, and the new findings, published in the Journal of the National Comprehensive Cancer Network, point to an accessible, low-risk path to relief.Honoring Dr. Rachna Shroff Through a New Young Investigator Award in Biliary Cancer
Association of American Cancer Institutes
AACI is pleased to announce that the Endowed Conquer Cancer – Rachna Shroff, MD, MS, FASCO Young Investigator Award in Biliary Cancer exceeded its goal of $1.35 million. Funded through the support of over 600 generous donors, the endowed award aims to ensure financial stability for early-career scientists focused on biliary, or bile duct, cancer research.
Cancer Center Founder to Retire After 46 Years
University of Michigan Rogel Cancer Center
Max S. Wicha, MD, founding director of the University of Michigan Rogel Cancer Center, will retire from the University of Michigan and move to emeritus status after 46 years of service. Dr. Wicha founded what is now the Rogel Cancer Center in 1986 and shepherded it to its first National Cancer Institute cancer center designation in 1988. Two years later the center earned comprehensive status, which it has maintained since.
Cancer Center Leaders Discuss Expanding Access to Care at TIME100 Health Leadership Forum
OHSU Knight Cancer Institute
On September 10, Eneida R. Nemecek, MD, MS, MBA, of OHSU Knight Cancer Institute, and David L. Porter, MD, of Abramson Cancer Center of the University of Pennsylvania, participated in an expert panel at the third annual TIME100 Health Leadership Forum in New York City. TIME senior health correspondent Alice Park moderated the panel, which also featured Amy Ronneberg, CEO of the National Marrow Donor Program.
Hope Lodge Chicago to Provide No-Cost Lodging to Patients and Caregivers
The University of Chicago Medicine Comprehensive Cancer Center
A facility that will provide free accommodations for cancer patients and their caregivers is being developed through a partnership between UChicago Medicine, the American Cancer Society, and community partners. Hope Lodge Chicago will be located about one mile from UChicago Medicine's 575,000-square-foot AbbVie Foundation Cancer Pavilion, scheduled to open in April 2027.
UVA Cancer Care to Expand With New Lynchburg Facility
University of Virginia Cancer Center
Patients will begin receiving care at a new UVA Cancer Center Lynchburg clinic later this fall. The new center will allow patients from Lynchburg who previously had to travel to the Emily Couric Clinical Cancer Center in Charlottesville to receive care locally. Most standard cancer treatments, including infusion therapies, will be available at the clinic through the UVA Comprehensive Cancer Center.
Construction Begins on New Huntsman Cancer Center in Vineyard
Huntsman Cancer Institute at the University of Utah
Community leaders, elected officials, supporters, and residents attended a cornerstone celebration marking the start of vertical construction on the future Huntsman Cancer Institute in Vineyard and recognizing Huntsman's long-term commitment to Vineyard, Utah County, and the families who will benefit from expanded access to cancer care, research, education, and innovation.
EDDY Unit to Expand Lung Cancer Screening
Roswell Park Comprehensive Cancer Center
Roswell Park is expanding the reach of its Early Detection Driven to You (EDDY) mobile cancer screening program with the addition of a more compact mobile lung cancer screening unit. Together with the EDDY Mobile Breast & Prostate Cancer Screening Center, the screening program will bring early detection services for the three most common invasive cancers directly to urban and rural communities in Western New York.
New Precision Surgical Approach to Diagnosing, Treating Early Lung Cancer
UCLA Jonsson Comprehensive Cancer Center
UCLA Health's thoracic surgery, interventional pulmonology, and pathology teams have adopted a novel, streamlined approach that combines diagnosis, staging, localization, and treatment into a single operating room session under one anesthetic event for select patients with suspected early-stage lung cancer.
Application Period Open for Immersive Postdoctoral Training Program
OHSU Knight Cancer Institute
The application window for the Experimental Therapeutics in Cancer Training Program at the OHSU Knight Cancer Institute, an immersive two-year postdoctoral training program for PhD and MD fellows, is open through Monday, November 2. The program bridges basic and clinical research to train future translational oncology scientists in therapeutic development, and fosters collaboration and creativity in developing novel cancer therapies.
UChicago Medicine Comprehensive Cancer Center Partners With Lilly to Expand Clinical Trial Access
The University of Chicago Medicine Comprehensive Cancer Center
Under a new two-year partnership between The University of Chicago Medicine Comprehensive Cancer Center and Lilly, the organizations will work together over time to expand access to clinical trials with innovative investigational therapies and improve the overall research experience. Unique elements to the partnership include dedicated project management, regular communication, and shared learning opportunities that provide a broad scope and long-term focus.
Roswell Park Breaks Ground on Community Outreach and Engagement Center Expansion
Roswell Park Comprehensive Cancer Center
Roswell Park broke ground on the expansion of their Broadview Community Outreach and Engagement Center, a project made possible through partnerships with New York State and Broadview Federal Credit Union. The enhanced space will support cancer education, prevention, and screening and reach historically underserved communities to reduce cancer disparities.Cancer Center Jobs
Associate Director for Administration | Senior Research Administrator
Houston Methodist Dr. Mary and Ron Neal Cancer Center
Read moreDivision Chief, Hematology/Oncology (Open Rank Tenure System Faculty) - Department of Medicine
University of Illinois Cancer Center
Read moreMeeting Announcements
2026 AACI Leadership Development Workshop
October 24, 2026
2026 Impact Summit
October 24, 2026
The 2026 Impact Summit will be held in conjunction with the 2026 AACI/CCAF Annual Meeting.
Co-hosted by AACI and the Cancer Center Network, the Impact Summit brings together cancer center leaders, researchers, and other stakeholders for a dynamic one-day event focused on strengthening the future of cancer center leadership and workforce development.
Support Opportunities
2026 New Cancer Center Directors Meeting
October 24, 2026
The 2026 New Cancer Center Directors Meeting will be held in conjunction with the 2026 AACI/CCAF Annual Meeting. Participation in this meeting is by invitation only. Please contact AACI Program Coordinator Chloe Boothby with any questions.
2026 AACI/CCAF Annual Meeting
October 25, 2026
The 3-day AACI/CCAF annual meeting offers AACI members the opportunity to network with cancer center colleagues, national cancer research and advocacy groups, industry, and government health agencies to develop solutions to common challenges.
Support Opportunities
2026 AACI Government Relations Forum
October 26, 2026
2:00 PM - 5:00 PM
Register today for the 2026 AACI Government Relations (GR) Forum. The GR Forum will be held from 2:00 to 5:00 pm central time on Monday, October 26, in conjunction with the 2026 AACI/CCAF Annual Meeting at the Chicago Marriott Downtown Magnificent Mile.
In addition to updates from AACI Sustaining Members, important announcements from the AACI GR Steering Committee, and opportunities to network and discuss public policy, highlights include updates on Operation TrialBlazer and the 2026 midterm elections and a presentation on the growth of biomedical research in China.
Advance registration is required. Participants are encouraged to register for the entire AACI/CCAF Annual Meeting, October 25-27, but may register for the GR Forum only, free of charge, by selecting "Government Relations Forum only" at registration.
Please contact AACI Director of Policy & Government Affairs Jaren Love with any questions.
Save the Date: Gordon Ginder Innovations in Cancer Symposium: ELEVATE Liver Cancer & MASH
April 8, 2027
Save the date for the VCU Massey Comprehensive Cancer Center's 2-day Gordon Ginder Innovations in Cancer Symposium: Liver Cancer and MASH, presented by Massey's ELEVATE P01 Program and the VCU Stravitz-Sanyal Institute. Registration coming soon.
Save the Date: 2027 AACI/AACR Hill Day
May 20, 2027
Save the date for the 2027 AACI/AACR Hill Day. More information to come.
Save the Date: 19th Annual AACI CRI Meeting
June 28, 2027
Save the date for the 19th Annual AACI Clinical Research Innovation (CRI) Meeting, June 28-30, 2027, at the Loews Chicago O'Hare Hotel in Rosemont, IL.
Save the Date: 2027 Catchment Area Data Excellence (CADEx) Conference
September 28, 2027
Save the date for the 2027 Catchment Area Data Excellence (CADEx) Conference, hosted by AACI in partnership with the Cancer Center Community Impact Forum. The conference will be held September 28-30, 2027, in Kansas City, MO. More information to come.
Save the Date: 2027 AACI/CCAF Annual Meeting
October 24, 2027
Save the date for the 2027 AACI/CCAF Annual Meeting, October 24-26, 2027, in Washington, DC. More information to come.
Save the Date: 20th Annual AACI Clinical Research Innovation (CRI) Meeting
July 20, 2028
Save the date for the 20th Annual AACI Clinical Research Innovation (CRI) Meeting, June 20-22, 2028, at the Loews Chicago O'Hare Hotel in Rosemont, IL. More information to come.